Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience

Author(s):
Osanto, S.; Hulle, T. van der
Published
2018
Publication type
Article / Letter to editor
AXLcabozantinibMETrenal cell cancertargeted therapytyrosine kinase inhibitorvascular endothelial growth factor receptor
Date issued
2018-03-31
Language
English
Is part of
Therapeutic Advances in Urology (2018), Vol. 10, no. 3, p. 109-123
hdl
1887/86708
doi
10.1177/1756287217748867
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896860/pdf/10.1177_1756287217748867.pdf